The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific

Similar documents
The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific

The epidemiology of tuberculosis

Table 1. Measles case classification and incidence by country and area, WHO Western Pacific Region,

TUBERCULOSIS CONTROL IN THE WHO WESTERN PACIFIC REGION In the WHO Western Pacific Region 2002 Report

Legend: No confirmed case With confirmed case** No case based data

Controlling TB in the era of HIV

Current status of implementation and monitoring and evaluation of collaborative TB/HIV activities. Avinash Kanchar

Figure 1. Incidence rate of total (confirmed and compatible) measles cases with rash onset 1 31 March 2018, WHO Western Pacific Region

Legend: No confirmed case With confirmed case No case based data

Figure 1. Incidence rate of total (confirmed and compatible) measles cases with rash onset 1 31 December 2018, WHO Western Pacific Region

Measles cases MCV1 coverage MCV2 coverage

Legend: No confirmed case With confirmed case No case based data

Figure 1. Incidence rate of total (confirmed and compatible) measles cases with rash onset 1 31 December 2017, WHO Western Pacific Region

The Western Pacific Region faces significant

Legend: No confirmed case With confirmed case No case based data

2009 Report. Tuberculosis Control. in the Western Pacific Region

Figure 1. Distribution of confirmed measles cases with rash onset 1 30 September 2014, WHO Western Pacific Region

Figure 1. Distribution of confirmed measles cases with rash onset 1 31 July 2014, WHO Western Pacific Region

HIV / AIDS & HUMAN RIGHTS

Figure 1. Confirmed measles cases, WHO Western Pacific Region, 1 31 March 2014

Figure 1. Distribution of confirmed measles cases with rash onset 1 31 August 2014, WHO Western Pacific Region

Legend: No confirmed case With confirmed case No case based data

Figure 1. Confirmed measles cases, WHO Western Pacific Region, 1 30 January 2014

Tuberculosis Control

Figure 1. Distribution of confirmed measles cases with rash onset 1 31 December 2014, WHO Western Pacific Region

Global, National, Regional

511,000 (57% new cases) ~50,000 ~30,000

Christian Gunneberg MO WHO The 14th Core Group Meeting of the TB/HIV Working Group November 11-12, 2008, Addis Ababa, Ethiopia

The United Nations flag outside the Secretariat building of the United Nations, New York City, United States of America

ASEAN Declaration of Commitment on HIV and AIDS: Fast-Tracking and Sustaining HIV and AIDS Responses To End the AIDS Epidemic by 2030

ON THE ROAD TO ENDING TB HIGHLIGHTS FROM THE 30 HIGHEST TB BURDEN COUNTRIES

Global, National, Regional

JOINT TB AND HIV PROGRAMMING

Mathematical modelling approach to estimating TB burden in children Pete Dodd (University of Sheffield) & James Seddon (Imperial College London)

Drug resistance TB in People Living with HIV: research questions and priorities.

Current State of Global HIV Care Continua. Reuben Granich 1, Somya Gupta 1, Irene Hall 2, John Aberle-Grasse 2, Shannon Hader 2, Jonathan Mermin 2

2010 global TB trends, goals How DOTS happens at country level - an exercise New strategies to address impediments Local challenges

Revitalising community engagement for TB and TB/HIV prevention, diagnosis and treatment

4/25/2012. The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB

2006 Report. Tuberculosis Control. in the Western Pacific Region

World Health Organization 2013

Collaborative TB and HIV Services for People Who Use Drugs

TB Disease Prevalence Survey - Progress Report

Copyright 2011 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved ISBN

WHO Global Task Force on TB Impact Measurement An overview

C R E A E. Consortium to Respond Effectively to the AIDS-TB Epidemic. An International Research Partnership

The WHO Global Project on anti-tb drug resistance surveillance: background, objectives, achievements, challenges, next steps

What can be done against XDR-TB?

TUBERCULOSIS CONTROL WHO WESTERN PACIFIC REGION

2010 Report. Tuberculosis Control. in the Western Pacific Region

XDR-TB Extensively Drug-Resistant Tuberculosis. What, Where, How and Action Steps

Essential Medicines. WHO

Population. B.4. Malaria and tuberculosis

Getting to zero HIV new infections in Asia and the Pacific region: Possible or impossible dream?

Estimating resource needs and gaps for harm reduction in Asia

Population. B.3. HIV and AIDS. There has been mixed progress in reducing new HIV infections and AIDSrelated

Appendix 3 Sample size and cost of surveys

WCPT COUNTRY PROFILE December 2017 JAPAN

Follow-up to the high-level meetings of the United Nations General Assembly on health-related issues

REVIEW OF TUBERCULOSIS EPIDEMIOLOGY

Progress, challenges and the way forward in ASEAN Member States

TB in the SEA Region. Review Plans and Progress. Dr Md Khurshid Alam Hyder Medical Officer TB SEARO/WHO

Ending the AIDS epidemic by 2030

Regional Response Plan for TB-HIV

Global Measles and Rubella Update November 2018

Review of new NSPs in Asia and the Pacific Region

EPIDEMIOLOGY OF TUBERCULOSIS AND the IMPACT ON CHILDREN

Global Measles and Rubella Update. April 2018

AIDS Funding Landscape in Asia and the Pacific

PROJECT DOCUMENT. Cooperative Agreement for Preventing the Spread of Communicable Diseases through Air Travel (CAPSCA)

TB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director

GLOBAL TUBERCULOSIS REPORT EXECUTIVE SUMMARY

Annex 2 A. Regional profile: West Africa

TB Disease Prevalence Survey - Overview, why and how

宮村参考人提出資料 資料 2-2

Technology and innovation: Changing dynamics of TB control. Karin Weyer

3.1 PHASE 2 OF THE GLOBAL PROJECT

Sexual and reproductive health care: A comparison of providers and delivery points between the African Region and other regions

aids in asia and the pacific

Action Plan to Reduce the Double Burden of Malnutrition in the Western Pacific Region. Dr Katrin Engelhardt, MPH Technical Lead, Nutrition DNH/WPRO

2. Treatment coverage: 3. Quality of care: 1. Access to diagnostic services:

Global Measles and Rubella Update October 2018

Tracking the HIV/AIDS epidemic in

Updates on the global TB Global TB burden Policy response Treatment approaches

How has the Polio Eradication Initiative influenced the global AIDS response? Bradley S. Hersh, MD, MPH

Tuberculosis: Opportunities and Challenges for Achieving HIV Epidemic Control

Call to Action. Global and Regional Hepatitis Action Plans: Opportunities and considerations for China

Investing for Impact

Disparities in access: renewed focus on the underserved. Rick Johnston, WHO UNC Water and Health, Chapel Hill 13 October, 2014

GOAL 2: ACHIEVE RUBELLA AND CRS ELIMINATION. (indicator G2.2) Highlights

Intensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite

The New WHO guidelines on intensified TB case finding and Isoniazid preventive therapy and operational considerations

7.5 South-East Asian Region: summary of planned activities, impact and costs

XDR and MDR TB Urgent Research Priorities. Gerald Friedland MD Yale School of Medicine Nelson R Mandela School of Medicine

World Health Organization HIV/TB Facts 2011

INH Prophylaxis Therapy (IPT) should NOT be implemented for all HIV patients in the Asia Pacific

Funding for AIDS: The World Bank s Role. Yolanda Tayler, WB Bi-regional Workshop for the Procurement of ARVs Phnom Penh, Cambodia

TB Disease Prevalence Survey - Overview and Introduction of the TF

Number of people receiving ARV therapy in developing and transitional countries by region,

This presentation discusses

Transcription:

Health System Strengthening and Sustaining the Response The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific Jintana Ngamvithayapong-Yanai, Ph.D. On behalf of TB/HIV Working Group, the Asia-Pacific The 9 th International Congress on AIDS in Asia and the Pacific (ICAAP) 10 August 2009: Plenary 2

From Mekhong to Bali: The Scale up of TB/HIV Collaborative Activities in Asia Pacific Region 8-9 August 2009, Bali 127 persons from 18 countries from Asia-Pacific (National TB Program, National AIDS Program, PLHIV, NGOs, Business sector, UNAIDS, WHO-HQ, WHO-SEARO, WHO-WPRO)

Outline Why TB? Why TB/HIV? WHO s TB/HIV Policy TB and TB/HIV Situation Progress in implementing TB/HIV collaborative activities in Asia-Pacific Patient and community contributing to TB/HIV prevention and care What next for TB/HIV in Asia-Pacific?

Abbreviations ARV = Antiretroviral drugs CPT = Co-trimoxazole preventive therapy PLHIV = People Living with HIV 3 I (three I) = Intensified TB Case Finding (ICF) Isoniazid Preventive therapy for TB (IPT) TB Infection Control

I miss my daughter Unfortunately, my daughter died after TB was cured because poor patients could t pay for anti-retroviral drugs. But w TB/HIV patients in my community can survive, they can live with their family and can feed the family. I miss my daughter. RIT-JATA and TB/HIV Research Foundation, Thailand

TB one of the oldest diseases (>4,000 years) RIT-JATA and TB/HIV Research Foundation, Thailand

In the old days TB was the disease of VIP Chopin, Pianist, composer Emperor Akihito Japan Nelson Mandela, former-president, South Africa RIT-JATA and TB/HIV Research Foundation, Thailand

22 countries with high TB burden in the world. Asia-Pacific account for 54% of global TB cases (WHO, 2008) RIT-JATA and TB/HIV Research Foundation, Thailand Burden ranking 1. India 2. China 3. Indonesia 4. Nigeria 5. Bangladesh 6. Nigeria 7. South Africa 8. Ethiopia 9. Philippines 10. Kenya 11. Democratic Republic of Congo 12. Rusian Federation 13. Viet Nam 14. Tanzania 15. Brazil 16. Uganda 17. Thailand 18. Mozambigue 19. Myanmar 20. Zimbabwe 21. Cambodia 22. Afghanistan 4

TB is transmitted by the tuberculosis patients who do t receive treatment (when coughing, sneezing, spitting, speaking) TB/HIV Research Project(RIT RIT-JATA)

Why worry about TB? TB/HIV Research Project (RIT-JATA) RIT-JATA and TB/HIV Research Foundation, Thailand

Most TB is curable even in PLHIV 4 drugs for 6-8 months Isoniazid, Rifampicin, Pyrazinamide, Ethambutol. http://www.textbookofbacteriology.net/tuberculosis_3.html

Why TB and HIV? Not TB infected Latent TB infection Active TB (disease) HIV infection (20-30 times risk) HIV is the most powerful kwn risk factor for reactivating latent TB infections into TB diseases TB is the leading cause of death in PLHIV About one-third of PLHIV are infected with TB RIT-JATA and TB/HIV Research Foundation, Thailand

WHO-2004 TB/HIV Activities

Collaboration of TB and AIDS programme Persons having TB Persons living with HIV HIV counseling and testing Screening for TB TB with HIV TB without HIV -TB treatment - TB treatment -CPT - HIV prevention -ARV -HIV prevention Yes -TB treatment No - IPT TB infection control RIT-JATA and TB/HIV Research Foundation, Thailand

What will happen? -A TB patient is waiting in the crowded setting for 3 hours especially in HIV or ARV clinic risk of TB transmission to other patients and health workers Photo credit: Dr.Supalert Natesuwan, Chiang Rai Hospital, Thailand

HIV prevalence among TB cases, 2007 HIV prevalence in TB cases, (%) No estimate 0 4 5 19 20 49 >= 50 Globally in 2007 1.4 million TB cases in PLHIV 450,000 TB/HIV deaths The boundaries and names shown and the designations used on this map do t imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may t yet be full agreement. WHO 2009. All rights reserved

Progress of HIV testing for tified TB patients Asia Pacific (47) 2004 18 0.3% 2005 22 2006 27 2007 29 Proportion of TB patients tested for HIV Key 1.9% No reported activity < 15% 15 to 50% 51 to 75% More than 75% 3.7% 0.2 of 3.1From million Mekong tifiedtotb Bali: patients were tested in ASIA PACIFIC REGION in 2007 The scale up of TB/HIV collaborative activities in Asia- Pacific, August 8-9, 2009 Denpasar, Bali, Indonesia 6.0%

ASIA PACIFIC 2007 Proportion of TB patients with kwn HIV status Country Proportion TB patients with HIV status kw 2007 Thailand Japan Malaysia Australia Cambodia Viet Nam Lao PDR Sri Lanka India China Myanmar Papua New Guinea Indonesia Philippines Source: WHO. Tuberculosis Report 2009. 69% 64% 60% 41% 39% 15% 11% 6% 5% 3% 2% 1% 0.10% 0.03%

HIV testing and treatment, 2007 Region TB patients HIV tested for HIV, prevalence in thousands (%) TB patients % of identified % of identified TB patients TB patients on CPT on ART South east Asia 122 (5.5%) 15% 37% 17% Western Pacific Region 95 (6.6%) 7% 45% 28% Source: WHO. Tuberculosis Report 2009.

Intensified TB finding among newly detected PLHIV in Thailand, 2006-8 % newly detected PHAs 100 90 89 93 81 80 70 60 Target 90 50 40 TB screening 30 20 8 12 14 10 0 2549 (2006) 2550 (2007) 2551 (2008) Source: Bureau of Tuberculosis Control, Dept of Disease Control, MopH Thailand, July 2009 Kwn HIV positive TB Patients

TB patients Newly HIV Tested: India 2005-2008 140,000 120,000 100,000 > 4 fold increase 91807 125756 Number 80,000 60,000 59654 40,000 20,000 29488 6411 (21%) 8785 (15%) 10426 (11%) 11870 (9%) 0 2005 2006 2007 2008 (upto Oct) No.of TB pts HIV tested No. detected HIV infected Source: Monthly reports from ICTCs collated and reported by respective State AIDS Control Societies

Policies and Services on TB/HIV in 2008 Country Services available to INH IPT as part Infection control screen TB for prophylaxis of HIV care policy for TB in PLHIV for PLHIV facilities Brunei Darussalam Cambodia China Fiji Lao PDR Malaysia Mongolia Papua New Guinea Philippines Singapore Viet Nam Source: Country reports for Universal Access Progress Report 2007 and 2008. Data of 2008 are provisional.

Trend of death rate in HIV positive TB patients and the coverage of ART in Chiang Rai province, Thailand (Source: TB/HIV Research Project, RIT-JATA, 2009) 100.0% 90.0% 80.0% 70.0% 60.0% Death 54.5% 60.4% 52.4% 51.6% 48.3% 47.7% 50.0% 41.3% 37.6% 40.0% 34.3% 29.1% 30.0% 28.3% 28.1% 29.4% 18.0% 20.0% 10.0% 55.9% 2.3% 4.8% ARV of TB patients 8.2% 0.0% 2000 2001 2002 2003 TB/HIV 774 769 674 733 2004 749 2005 2006 2007 2008 693 543 508 442

Isoniazid reduces risk of TB in HIV-positive: PLHIV cohort in Chiang Rai Province, Preliminary analysis: observation time from September 2002 to December 2008 N TB Relative 95 % Non TB risk Ratio confidence (crude) interval No IPT 1,483 164 1,319 IPT 390 11 379 Source: TB/HIV Research Project (RIT-JATA) 4.28 1 P value 2.30- <0.001 8.84 -

Two diseases many pill burdens Photo credit: Dr,Somsak Akkasil, CDC 7, Ubon, Thailand

How do poor patients adhere to TB and ARV treatment? Temple s bell mortar-pestle chicken s crow RIT-JATA and TB/HIV Research Foundation, Thailand

Once in my life someone called me brother RIT-JATA and TB/HIV Research Foundation, Thailand Doctor who think TB/HIV and involved patient network for TB/HIV care

Patient network

Next steps TB and HIV communities need to collaborate more closely To stop people living with HIV from dying of TB To reach the most vulnerable populations (IDU, prisoners, migrant populations) To strengthen the systems that support health Laboratory strengthening, drug procurement Engaging communities in the response Engaging other sectors justice, labour..